Skip to main content

Advertisement

Table 1 Baseline characteristics table (N = 214)

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

   N (%) or Median(min-max)
Age (years)   58 (26–81)
Gender Male 166 (77.6)
Female 48 (22.4)
Nephrectomy No 90 (42.1)
Yes 121 (56.5)
Unknown 3 (1.4)
Treatment free interval ≥1 yr 56 (26.2)
<  1 yr 158 (73.8)
Anemia Normal 44 (20.6)
Hb < 13.5/12.0 (M/F) 170 (79.4)
Hypercalcemia Normal 180 (84.1)
> 10 mg/dL or 2.5 mmol/L 28 (13.1)
Unknown 6 (2.8)
Neutrophilia Normal 174 (81.3)
< 1500 or > 7500 33 (15.4)
Unknown 7 (3.3)
Elevated LDH Normal 96 (44.9)
>×1.5ULN 49 (22.9)
unknown 69 (32.2)
KPS >  80 204 (95.3)
≤ 80 4 (1.9)
unknown 6 (2.8)
Thrombocytosis Normal 192 (89.7)
>  400 K 22 (10.3)
Therapy Immunotherapy 126 (58.9)
Target Therapy 88 (41.1)
Heng Intermediate risk 171 (79.9)
Poor risk 43 (20.1)
Tumor (T) T1 - T2 96 (44.9)
T3 -T4 61 (28.5)
Unknown 57 (26.6)
Lymph node(N) N0 54 (25.2)
N1 45 (21.0)
Nx 30 (14.0)
Unknown 85 (39.7)
Metastasis cM0 27 (12.6)
cM1 81 (37.9)
pM1 2 (0.9)
cMx 3 (1.4)
Unknown 101 (47.2)
mRCC type Synchronous mRCC 144 (67.3)
Metachronous mRCC 70 (32.7)
Fuhrman nuclear grade G1-G2 41 (19.2)
G3-G4 101 (47.2)
Unknown 72 (33.6)
Histology Clear cell 164 (76.6)
Non-clear cell 12 (5.6)
Unknown 38 (17.8)
Treatment duration (Month) 4.2 (1.0–70.4)
Follow-up duration (Month) 98.3 (4.8–147.6)
Progression free survival (Month, median(95%CI)) 4.7 (3.8–5.5)
Cancer-specific survival (Month, median(95%CI)) 13.8 (9.8–18.3)
Cancer-specific survival status Censored/ Event 32 (15.0)/ 182 (85.0)
Progression-free survival status Censored/ Event 21 (9.8)/ 193 (90.1)